---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-006793"
form_type: "8-K"
ticker: "CBIO"
cik: "0001253689"
company_name: "CRESCENT BIOPHARMA, INC."
filed_at: "2024-05-06T23:59:59+00:00"
generated_at: "2026-06-02T21:47:30.360621+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.95
calibrated_materiality_score: 0.95
confidence: "high"
source: SEC EDGAR
---

# GlycoMimetics' pivotal Phase 3 trial of uproleselan in R/R AML fails to meet primary endpoint of overall survival

## Summary
- Phase 3 study (388 patients) of uproleselan + chemo did not achieve statistically significant improvement in overall survival vs chemo alone.
- Median overall survival 13 months (uproleselan) vs 12.3 months (placebo).
- NCI Phase 2/3 study in newly diagnosed AML remains ongoing; company will submit data to medical meeting.
- Cash and cash equivalents $31.3M as of March 31, 2024, down from $41.8M at Dec 31, 2023.
- Q1 2024 R&D expenses $6.0M, G&A $5.1M; shares outstanding 64.5M.

## SEC filing metadata
- accession: 0001558370-24-006793
- form_type: 8-K
- ticker: CBIO
- cik: 0001253689
- company_name: CRESCENT BIOPHARMA, INC.
- filed_at: 2024-05-06T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.95
- calibrated_materiality_score: 0.95
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1253689/000155837024006793/0001558370-24-006793-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1253689/000155837024006793/glyc-20240506x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-006793
- JSON: https://secwatch.observer/filing/0001558370-24-006793.json
- Plain text: https://secwatch.observer/filing/0001558370-24-006793.txt

## Key facts
- Earnings Releases
  CRESCENT BIOPHARMA, INC. reported preliminary financial results for first quarter of 2024.
  - Period: first quarter of 2024
  - Result: preliminary results
  source text: On May 6, 2024, GlycoMimetics, Inc. (the “ Company ”) issued a press release announcing, in addition to the information described in Item 7.01 below, its financial results for the first quarter ended March 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1253689/000155837024006793/0001558370-24-006793-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.